Although it has shown impressive anti-tumor activity in preclinical mouse models, its potential clinical use may face obstacles due to CLDN4's widespread expression in many normal tissues, which raises concerns about possible toxicity in healthy tissues. Here, CLDN4 is linked to neoplasm.